Nuformix PLC Additional New NXP002 Patent Filing (2560C)
September 28 2018 - 2:02AM
UK Regulatory
TIDMNFX
RNS Number : 2560C
Nuformix PLC
28 September 2018
28 September 2018
Nuformix plc
("Nuformix" or the "Company")
Additional New NXP002 Patent Filing
Nuformix, the pharmaceutical development company using cocrystal
technology to unlock the therapeutic potential of approved small
molecule drugs is pleased to announce a new patent filing in
connection with its NXP002 fibrosis programme.
Fibrotic disease is typically associated with high patient
mortality, increasing prevalence and a lack of safe and effective
treatments. Whilst, fibrosis treatments are in their infancy the
emerging lung fibrosis market demonstrates their blockbuster
potential. Markets for other fibrotic conditions are
under-developed, with large and growing patient populations (e.g.
the global liver disease market is predicted to reach $12.1 billion
by 2022).
Using cutting-edge human tissue disease models, Nuformix has
previously demonstrated the potential for NXP002 to attenuate
progression in established lung and liver fibrosis. This additional
patent filing provides further strength and breadth to the existing
NXP002 patent portfolio to best support further development and
commercialisation for its NXP002 programme.
Dr Dan Gooding, CEO, Nuformix plc, said: "NXP002 has
demonstrated its broad anti-fibrotic potential with relevance to
unmet needs in multiple life threatening conditions. Our additional
patent filing strengthens Nuformix's ability to consider a wider
range of options in the treatment of fibrosis. We hope to report
shortly on the results of our extended study in idiopathic lung
fibrosis using a highly innovative new human tissue model.
Broadening and protecting the applications for NXP002 with this
additional IP filing creates the potential to deliver wider benefit
for patients whilst maximising value for investors."
www.nuformix.com
Market Abuse Regulation (MAR) Disclosure. Certain information
contained in this announcement would have been deemed inside
information for the purposes of Article 7 of Regulation (EU) No
596/2014 until the publication of this announcement via a
Regulatory Information Service and accordingly, this inside
information is now considered to be in the public domain.
Enquiries:
Nuformix plc
Dr Dan Gooding, Chief Executive
Officer +44 (0)1223 423667
Gable Communications Ltd
John Bick / Justine James +44 (0)20 7193 7463
About Nuformix plc www.nuformix.com
Nuformix is a pharmaceutical development company using cocrystal
technology to unlock the therapeutic potential of approved small
molecule drugs. Nuformix's risk-mitigated development strategy has
resulted in a pipeline of discoveries through which it has
developed and patented novel cocrystal forms of approved small
molecules.
Nuformix has created an IP portfolio containing a range of
granted patents covering cocrystal forms of five small molecule
drugs. Nuformix is targeting high-value unmet needs with its lead
programmes in oncology supportive care: NXP001 and fibrosis:
NXP002.
Nuformix was established in Cambridge in 2009 and has invested
into pharmaceutical cocrystal R&D, establishing world-class
capability and know-how in cocrystal discovery and development,
yielding multiple product opportunities. Nuformix plc shares are
traded on the London Stock Exchange's Official List under the
ticker: NFX.L.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCMMGZLZNMGRZZ
(END) Dow Jones Newswires
September 28, 2018 02:02 ET (06:02 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From Apr 2023 to Apr 2024